MAX SENNA MANO
Projetos de Pesquisa
Unidades Organizacionais
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
1 resultados
Resultados de Busca
Agora exibindo 1 - 1 de 1
- Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE(2022) LOIBL, Sibylle; HUANG, Chiun-Sheng; MANO, Max S.; MAMOUNAS, Eleftherios P.; GEYER, Charles E.; UNTCH, Michael; THERY, Jean-Christophe; SCHWANER, Ingo; LIMENTANI, Steven; LOMAN, Niklas; LUBBE, Kristina; CHANG, Jenny C.; HATSCHEK, Thomas; TESAROWSKI, David; SONG, Chunyan; HAAS, Sanne Lysbet de; BOULET, Thomas; LAMBERTINI, Chiara; WOLMARK, NormanFollowing chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.